SINOHEALTH HLDG (02361) Elevates Corporate Strategy from "Digital Intelligence Solutions Provider in Life Sciences" to "AI Technology Services Firm Anchored by Health Industry Data Assets and Ecosystem Resources"

SINOHEALTH HLDG (02361) announced that, effective the date of this announcement, the company's strategy will be formally upgraded from being a "digital intelligence solutions provider in the life sciences field" to advancing towards becoming an "AI technology services company based on health industry data elements and ecological resources." This strategic evolution from "data technology services" to "AI decision-making and intelligent services" is founded on the integrated capabilities the company is building around "data + models + scenarios + ecosystem": 1. Dual-domain large models progressing from "cognition to decision-making": (1) Zhuomuniao (Medical Large Model): Trained on medical literature, patient records, and pharmacological knowledge graphs, this model has been evaluated by medical experts and demonstrates superior professionalism and accuracy in comprehending complex medical terminology and compliance requirements. (2) Tiangang-1 (Decision-Making Large Model): Deeply integrated with years of accumulated diverse market data and industry logic, while also incorporating medical knowledge, it possesses the ability to translate insights into concrete marketing strategies, resource allocation plans, and professional sales execution, dedicated to achieving a value cycle from "medical cognition" to "business outcomes." 2. Multi-dimensional data moat and industry intelligence brain: The company possesses diversified health industry data resources, covering a wide range of medical institutions,体检机构, and pharmacies, constructing a comprehensive data system spanning from in-hospital to out-of-hospital, online to offline, and prevention to treatment. Simultaneously, leveraging 18 years of industry know-how, it deciphers the business logic behind the data, deconstructs complex business scenarios, and aids critical decision-making. 3. Comprehensive AI service system and team collaboration capabilities: The company has established an AI service system ranging from foundational infrastructure to front-end applications. Based on multi-dimensional service models, it possesses the capability to serve the diverse needs of clients from small and medium-sized enterprises to large corporate groups; its team and partners combine top-tier AI technology with deep pharmaceutical experience, and it will continue to deeply integrate technology with medical scenarios to ensure product implementation and create quantifiable value. Guided by the latest corporate strategy, SINOHEALTH will fully utilize its core competencies to build AI implementations for four key scenarios in the health industry: marketing, healthcare, pharmacies, and health management, thereby driving industry transformation and upgrading. On the marketing front, the company is launching commercial AI agents and, based on the "Tiangang-1" decision-making model, aims to achieve more efficient generation and implementation of marketing strategies, empowering pharmaceutical companies to reduce costs and increase efficiency. For the healthcare sector, supported by the company's self-developed "Zhuomuniao" medical model, the focus will be on developing the "iMDT" intelligent agent for multi-disciplinary team consultations on critical illnesses, enhancing the quality of MDT decisions to empower doctors and hospitals more precisely. Regarding the pharmacy segment, as enhancing professional service capabilities is crucial for their performance growth, the company will make breakthroughs and drive implementation across five dimensions: operational insights, merchandise, disease categories, membership, and staff, assisting pharmacies in achieving intelligent closed-loop management from product selection to member services. In the health management sector, the company will commit to developing a comprehensive "prevention-screening-intervention" health management system. By constructing a multi-dimensional matrix of intelligent agents, it will provide more precise services for health management, patient medication, and rehabilitation guidance. Moving forward, the company will adhere to its established development strategy, using industrial-scale data as a foundation to build an efficient collaborative ecosystem of health industry intelligent agents, continuously leading the industry into a new era of intelligent transformation.